KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Michael L WangJavier MunozAndre GoyFrederick L LockeCaron A JacobsonBrian T HillJohn M TimmermanHouston HolmesSamantha JaglowskiIan W FlinnPeter A McSweeneyDavid B MiklosJohn M PagelMarie-Jose KerstenNoel MilpiedHenry FungMax S ToppRoch HouotAmer BeitinjanehWeimin PengLianqing ZhengJohn M RossiRajul K JainArati V RaoPatrick M ReaganPublished in: The New England journal of medicine (2020)
KTE-X19 induced durable remissions in a majority of patients with relapsed or refractory mantle-cell lymphoma. The therapy led to serious and life-threatening toxic effects that were consistent with those reported with other CAR T-cell therapies. (Funded by Kite, a Gilead company; ZUMA-2 ClinicalTrials.gov number, NCT02601313.).